KAG-308 is an orally active, selective EP4 (prostaglandin E2 receptor subtype 4) agonist with demonstrated anti-inflammatory and anti-fibrotic properties. In preclinical models, KAG-308 showed potent EP4 agonistic activity with an EC₅₀ of 1.9 nM in cAMP accumulation assays using EP4-expressing cells. In mouse models of pulmonary fibrosis, oral administration of KAG-308 at 1–3 mg/kg significantly reduced lung fibrosis markers, including hydroxyproline content and TGF-β1 expression. Additionally, in collagen-induced arthritis models, KAG-308 treatment reduced joint swelling and inflammatory cytokine production, with efficacy comparable to or better than standard anti-inflammatory agents. These data support KAG-308 as a promising therapeutic candidate for inflammatory and fibrotic diseases.
MedKoo Cat#: 555556
Name: KAG-308
CAS#: 1215192-68-9
Chemical Formula: C24H30F2N4O3
Exact Mass: 460.2286
Molecular Weight: 460.53
Elemental Analysis: C, 62.59; H, 6.57; F, 8.25; N, 12.17; O, 10.42
The following data is based on the product molecular weight 460.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
